364 related articles for article (PubMed ID: 21084273)
1. An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity.
Wynendaele J; Böhnke A; Leucci E; Nielsen SJ; Lambertz I; Hammer S; Sbrzesny N; Kubitza D; Wolf A; Gradhand E; Balschun K; Braicu I; Sehouli J; Darb-Esfahani S; Denkert C; Thomssen C; Hauptmann S; Lund A; Marine JC; Bartel F
Cancer Res; 2010 Dec; 70(23):9641-9. PubMed ID: 21084273
[TBL] [Abstract][Full Text] [Related]
2. miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia.
Ovcharenko D; Stölzel F; Poitz D; Fierro F; Schaich M; Neubauer A; Kelnar K; Davison T; Müller-Tidow C; Thiede C; Bornhäuser M; Ehninger G; Brown D; Illmer T
Exp Hematol; 2011 Oct; 39(10):1030-1042.e7. PubMed ID: 21784052
[TBL] [Abstract][Full Text] [Related]
3. Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2.
Chao A; Lin CY; Lee YS; Tsai CL; Wei PC; Hsueh S; Wu TI; Tsai CN; Wang CJ; Chao AS; Wang TH; Lai CH
Oncogene; 2012 Feb; 31(6):764-75. PubMed ID: 21725366
[TBL] [Abstract][Full Text] [Related]
4. The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer.
Gansmo LB; Bjørnslett M; Halle MK; Salvesen HB; Dørum A; Birkeland E; Hveem K; Romundstad P; Vatten L; Lønning PE; Knappskog S
Tumour Biol; 2016 Aug; 37(8):10697-702. PubMed ID: 26867771
[TBL] [Abstract][Full Text] [Related]
5. A genetic variant of MDM4 influences regulation by multiple microRNAs in prostate cancer.
Stegeman S; Moya L; Selth LA; Spurdle AB; Clements JA; Batra J
Endocr Relat Cancer; 2015 Apr; 22(2):265-76. PubMed ID: 25670033
[TBL] [Abstract][Full Text] [Related]
6. MiR-196a binding-site SNP regulates RAP1A expression contributing to esophageal squamous cell carcinoma risk and metastasis.
Wang K; Li J; Guo H; Xu X; Xiong G; Guan X; Liu B; Li J; Chen X; Yang K; Bai Y
Carcinogenesis; 2012 Nov; 33(11):2147-54. PubMed ID: 22859270
[TBL] [Abstract][Full Text] [Related]
7. Genetic variation in an miRNA-1827 binding site in MYCL1 alters susceptibility to small-cell lung cancer.
Xiong F; Wu C; Chang J; Yu D; Xu B; Yuan P; Zhai K; Xu J; Tan W; Lin D
Cancer Res; 2011 Aug; 71(15):5175-81. PubMed ID: 21676885
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-kappaB1.
Guo LM; Pu Y; Han Z; Liu T; Li YX; Liu M; Li X; Tang H
FEBS J; 2009 Oct; 276(19):5537-46. PubMed ID: 19702828
[TBL] [Abstract][Full Text] [Related]
9. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration.
Sarver AL; Li L; Subramanian S
Cancer Res; 2010 Dec; 70(23):9570-80. PubMed ID: 21118966
[TBL] [Abstract][Full Text] [Related]
11. RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression.
Chen X; Chen S; Xiu YL; Sun KX; Zong ZH; Zhao Y
Mol Cancer; 2015 Feb; 14(1):31. PubMed ID: 25649143
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-494 downregulates KIT and inhibits gastrointestinal stromal tumor cell proliferation.
Kim WK; Park M; Kim YK; Tae YK; Yang HK; Lee JM; Kim H
Clin Cancer Res; 2011 Dec; 17(24):7584-94. PubMed ID: 22042971
[TBL] [Abstract][Full Text] [Related]
13. p53 gene mutations and codon 72 polymorphism in ovarian carcinoma patients from Serbia.
Malisic E; Jankovic R; Slavkovic D; Milovic-Kovacevic M; Radulovic S
J BUON; 2010; 15(1):101-6. PubMed ID: 20414935
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells.
Salvi A; Sabelli C; Moncini S; Venturin M; Arici B; Riva P; Portolani N; Giulini SM; De Petro G; Barlati S
FEBS J; 2009 Jun; 276(11):2966-82. PubMed ID: 19490101
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth.
Corney DC; Flesken-Nikitin A; Godwin AK; Wang W; Nikitin AY
Cancer Res; 2007 Sep; 67(18):8433-8. PubMed ID: 17823410
[TBL] [Abstract][Full Text] [Related]
16. G-A variant in miR-200c binding site of EFNA1 alters susceptibility to gastric cancer.
Li Y; Nie Y; Cao J; Tu S; Lin Y; Du Y; Li Y
Mol Carcinog; 2014 Mar; 53(3):219-29. PubMed ID: 23065816
[TBL] [Abstract][Full Text] [Related]
17. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis.
Shen J; Ambrosone CB; DiCioccio RA; Odunsi K; Lele SB; Zhao H
Carcinogenesis; 2008 Oct; 29(10):1963-6. PubMed ID: 18660546
[TBL] [Abstract][Full Text] [Related]
18. Association of a genetic variation in a miR-191 binding site in MDM4 with risk of esophageal squamous cell carcinoma.
Zhou L; Zhang X; Li Z; Zhou C; Li M; Tang X; Lu C; Li H; Yuan Q; Yang M
PLoS One; 2013; 8(5):e64331. PubMed ID: 23724042
[TBL] [Abstract][Full Text] [Related]
19. Variations within 3'-UTR of MDM4 gene contribute to clinical outcomes of advanced non-small cell lung cancer patients following platinum-based chemotherapy.
Yang Y; Gao W; Ding X; Xu W; Liu D; Su B; Sun Y
Oncotarget; 2017 Mar; 8(10):16313-16324. PubMed ID: 27462918
[TBL] [Abstract][Full Text] [Related]
20. [Expression and significance of microRNAs in the p53 pathway in ovarian cancer cells and serous ovarian cancer tissues].
Zhang Q; He XJ; Ma LP; Li N; Yang J; Cheng YX; Cui H
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):885-90. PubMed ID: 22340095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
